irinotecan + raltitrexed + docetaxel

Irinotecan + raltitrexed + docetaxel is an experimental combination chemotherapy regimen consisting of three cytotoxic agents with distinct mechanisms of action. Irinotecan is a camptothecin derivative that inhibits DNA topoisomerase I, preventing DNA religation and causing lethal double-strand breaks. Raltitrexed is a folate analogue that specifically inhibits thymidylate synthase, thereby disrupting DNA synthesis. Docetaxel is a taxane that promotes the assembly of microtubules and inhibits their depolymerization, leading to cell cycle arrest in the G2/M phase. This triple combination, often referred to as the DIR or IRD regimen in the context of solid tumor research, has been investigated in Phase 1 clinical trials to determine the maximum tolerated dose and safety profile in patients with advanced solid malignancies, such as gastrointestinal cancers. It is important to note that while the provided context associates this name with a Multiple Myeloma trial (ChiCTR1900024917) and Beijing Jishuitan Hospital, that trial actually evaluates a different IRD regimen composed of ixazomib, lenalidomide (Revlimid), and dexamethasone; the expansion of the 'IRD' acronym to 'irinotecan + raltitrexed + docetaxel' appears to be a misidentification in the source context.

Other names

DIR regimenIRD regimen